An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Phamacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (WAIHA) or Cold Agglutininin Disease (CAD)
Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer
Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (KTE-C19) Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant
A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment
A prospective, multinational, multi-center, phase 2, randomized, controlled, open-label study evaluating the efficacy, safety, tolerability and pharmacokinetics of sig12d-loder in the treatment of patients with unresectable locally advanced pancreatic cancer when used in conjunction with standard chemotherapy (gemcitabine+nab-paclitaxel) versus chemotherapy (gemcitabine+nab-paclitaxel) alone
Phase 2a study (Part 1) – A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC-0084 administered to patients with glioblastoma multiforme characterized by unmethylated O6-methylguaninemethyltransferase promoter status. Phase 2b study (Part 2) – A randomized, open-label, multicenter, phase 2b study to assess the efficacy and safety of the PI3K/mTOR inhibitor GDC-0084 compared to temozolomide as adjuvant therapy for the treatment of newly diagnosed glioblastoma multiforme with unmethylated O6-methylguanine-methyltransferase promoter status following surgical resection and standard concomitant chemoradiation therapy with temozolomide
An Open-Label Phase 1/2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma
